Hepatitis B surface antigen-derived peptide–Major Histocompatibility Complex class II complex (HBsAg-pMHC II)

The Hepatitis B surface antigen (HBsAg)-derived peptide–Major Histocompatibility Complex class II (MHC II) complex is a molecular assembly essential for the adaptive immune recognition of the Hepatitis B virus (HBV). It consists of an exogenous HBsAg protein fragment, typically 13–25 amino acids in length, non-covalently bound within the peptide-binding groove of an MHC II molecule such as HLA-DR, DQ, or DP [Source: Roche & Furuta, 2015, Nature Reviews Immunology]. These complexes are primarily expressed on the surface of professional antigen-presenting cells like dendritic cells, where they serve as the primary ligand for the T-cell receptors (TCRs) of CD4+ T lymphocytes [Source: Boni et al., 2007, Journal of Virology]. Recognition of the HBsAg-pMHC II complex by specific CD4+ T cells is a cornerstone of the antiviral response, as it orchestrates the activation of B cells for antibody production and provides necessary cytokines to sustain CD8+ T cell effector functions [Source: Bertoletti & Ferrari, 2016, Gastroenterology]. In chronic HBV infection, the immune system often fails to maintain an effective response to these complexes, leading to T-cell exhaustion and viral persistence [Source: Ye et al., 2015, Frontiers in Immunology]. Consequently, the HBsAg-pMHC II complex is a major target for therapeutic interventions, including therapeutic vaccines like GS-4774 and VTP-300, as well as experimental TCR-engineered T-cell therapies designed to bypass natural immune tolerance [Source: Meng et al., 2021, Frontiers in Immunology]. By enhancing the frequency and activity of CD4+ T cells that recognize these complexes, researchers aim to achieve a "functional cure" for HBV, characterized by sustained HBsAg loss and immune control [Source: Lok et al., 2016, Lancet Infectious Diseases]. However, therapeutic targeting of this complex carries risks, such as inflammatory liver flares and cytokine release syndrome, necessitating careful monitoring of liver enzymes and systemic immune markers [Source: Bertoletti & Gehring, 2013, Journal of Hepatology].

Other names

HBsAg-peptide-HLA-II complexHBsAg-pMHCIIHepatitis B surface antigen peptide-MHC class II complexHBsAg-HLA-DR complex

The complex acts as a specific ligand for the CD4+ T-cell receptor (TCR). Binding initiates a signaling cascade involving the CD3 complex and ZAP-70, leading to T-cell activation, secretion of antiviral cytokines like IFN-gamma and TNF-alpha, and the provision of help to B cells for anti-HBs antibody production [Source: Roche & Furuta, 2015, Nature Reviews Immunology; Bertoletti & Ferrari, 2016, Gastroenterology].